Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Octagon Therapeutics

Octagon is focused on developing targeted medicines for autoimmunity.  This new class of immunomodulators is activated by disease-related biology, ideal for episodic chronic disorders.  A lead program inhibits autoreactive B-cells that drive pemphigus, RA, and other autoimmune diseases.

  • Isaac Stoner COO
  • Peter Yu CTO
  • Fred Ausubel CSO
  • Brent Cezairliyan VP Biology
  • Nat Sherden VP Chemistry
  • Luis Castillo-Menendez Principal Scientist
  • Zhining Cao Senior Scientist